ENTRADA THERAPEUTICS, INC. Research and Development Expense
ENTRADA THERAPEUTICS, INC. (TRDA) reported Research and Development Expense of $35.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $35.37M, a 6.62% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $33.05M, a 3.06% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $33.96M, a 1.65% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $38.36M, a 22.73% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $142.27M, a 13.54% increase from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $125.31M, a 25.45% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. research and development expense for fiscal 2023 was $99.88M, a 49.96% increase from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. research and development expense for fiscal 2022 was $66.61M, a 85.41% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.37M 10-Q · filed 2026-08-05 | $68.42M 10-Q · filed 2026-08-05 | $102.38M derived: sum of 3 quarters · filed 2026-08-05 | $140.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $33.05M 10-Q · filed 2026-05-07 | $67.01M derived: sum of 2 quarters · filed 2026-05-07 | $105.37M derived: sum of 3 quarters · filed 2026-05-07 | $143.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $33.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $72.32M derived: sum of 2 quarters · filed 2026-02-26 | $110.19M derived: sum of 3 quarters · filed 2026-08-05 | $142.27M 10-K · filed 2026-02-26 |
| 2025-09-30 | $38.36M 10-Q · filed 2025-11-06 | $76.24M derived: sum of 2 quarters · filed 2026-08-05 | $108.31M 10-Q · filed 2025-11-06 | $141.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $37.88M 10-Q · filed 2026-08-05 | $69.95M 10-Q · filed 2026-08-05 | $103.36M derived: sum of 3 quarters · filed 2026-08-05 | $134.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $32.07M 10-Q · filed 2026-05-07 | $65.48M derived: sum of 2 quarters · filed 2026-05-07 | $96.74M derived: sum of 3 quarters · filed 2026-05-07 | $128.77M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $33.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $64.66M derived: sum of 2 quarters · filed 2026-02-26 | $96.70M derived: sum of 3 quarters · filed 2026-02-26 | $125.31M 10-K · filed 2026-02-26 |
| 2024-09-30 | $31.26M 10-Q · filed 2025-11-06 | $63.29M derived: sum of 2 quarters · filed 2025-11-06 | $91.90M 10-Q · filed 2025-11-06 | $120.19M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $32.03M 10-Q · filed 2025-08-06 | $60.64M 10-Q · filed 2025-08-06 | $88.93M derived: sum of 3 quarters · filed 2025-08-06 | $111.13M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $28.61M 10-Q · filed 2025-05-08 | $56.90M derived: sum of 2 quarters · filed 2025-05-08 | $79.09M derived: sum of 3 quarters · filed 2025-05-08 | $105.39M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $28.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $50.48M derived: sum of 2 quarters · filed 2025-02-27 | $76.78M derived: sum of 3 quarters · filed 2025-02-27 | $99.88M 10-K · filed 2025-02-27 |
| 2023-09-30 | $22.19M 10-Q · filed 2024-11-05 | $48.49M derived: sum of 2 quarters · filed 2024-11-05 | $71.59M 10-Q · filed 2024-11-05 | $87.28M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $26.30M 10-Q · filed 2024-08-13 | $49.40M 10-Q · filed 2024-08-13 | $65.09M derived: sum of 3 quarters · filed 2024-08-13 | $84.05M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $23.10M 10-Q · filed 2024-05-07 | $38.79M derived: sum of 2 quarters · filed 2024-05-07 | $57.74M derived: sum of 3 quarters · filed 2024-05-07 | $73.99M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $15.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $34.64M derived: sum of 2 quarters · filed 2024-03-13 | $50.89M derived: sum of 3 quarters · filed 2024-03-13 | $66.61M 10-K · filed 2024-03-13 |
| 2022-09-30 | $18.96M 10-Q · filed 2023-11-07 | $35.21M derived: sum of 2 quarters · filed 2023-11-07 | $50.92M 10-Q · filed 2023-11-07 | $63.29M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $16.25M 10-Q · filed 2023-08-08 | $31.97M 10-Q · filed 2023-08-08 | $44.33M derived: sum of 3 quarters · filed 2023-08-08 | $54.84M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $15.72M 10-Q · filed 2023-05-10 | $28.08M derived: sum of 2 quarters · filed 2023-05-10 | $38.59M derived: sum of 3 quarters · filed 2023-05-10 | $45.42M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $12.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $22.88M derived: sum of 2 quarters · filed 2023-03-06 | $29.70M derived: sum of 3 quarters · filed 2023-03-06 | $35.93M 10-K · filed 2023-03-06 |
| 2021-09-30 | $10.51M 10-Q · filed 2022-11-07 | $17.34M derived: sum of 2 quarters · filed 2022-11-07 | $23.56M 10-Q · filed 2022-11-07 | $30.22M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $6.83M 10-Q · filed 2022-08-11 | $13.05M 10-Q · filed 2022-08-11 | $19.71M derived: sum of 3 quarters · filed 2022-08-11 | $25.41M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $6.22M 10-Q · filed 2022-05-12 | $12.88M derived: sum of 2 quarters · filed 2022-05-12 | $18.58M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $6.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $12.36M derived: sum of 2 quarters · filed 2022-03-15 | $21.10M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $5.70M 10-Q · filed 2021-12-09 | $14.45M 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |